Why Avidity Biosciences Zoomed to a 12% Gain This Week [Yahoo! Finance]
Avidity Biosciences, Inc. (RNA)
Company Research
Source: Yahoo! Finance
Clinical-stage biotech Avidity Biosciences (NASDAQ: RNA) had some good news to report toward the end of this week, and investors rewarded it by piling into the company's stock. By the close of trading Friday, said equity had risen almost 12% in value across the week, according to data compiled by S&P Global Market Intelligence Partial clinical hold released On Thursday, Avidity announced that the U.S. Food and Drug Administration (FDA) has released its partial clinical hold on one of the biotech company's investigational drugs. This is delpacibart etedesiran (del-desiran), also known as AOC 1001, a medication aimed at combating a form of muscular dystrophy called myotonic dystrophy type 1. The drug is being tested in a phase 3 clinical trial. In 2022, the FDA placed its hold following news of a patient experiencing a serious adverse event. Avidity did not disclose the nature of that event, banning the recruitment of new patients. The regulator relaxed that hold, allowing the co
Show less
Read more
Impact Snapshot
Event Time:
RNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNA alerts
High impacting Avidity Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RNA
News
- Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $65.00 price target on the stock.MarketBeat
- Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.MarketBeat
- Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology InnovationsPR Newswire
- Avidity Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]Yahoo! Finance
RNA
Earnings
- 8/9/24 - Beat
RNA
Sec Filings
- 11/20/24 - Form 4
- 11/20/24 - Form 4
- 11/14/24 - Form SC
- RNA's page on the SEC website